Enzymatica AB (publ) (ENZY.ST)
SEK 1.68
(-1.18%)
SEK 1.68
(-1.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 79.92 Million SEK | -14.04% |
| 2022 | 96.67 Million SEK | 22.99% |
| 2021 | 78.59 Million SEK | -10.7% |
| 2020 | 88.02 Million SEK | 1.69% |
| 2019 | 86.55 Million SEK | 11.85% |
| 2018 | 77.38 Million SEK | 16.3% |
| 2017 | 66.53 Million SEK | -2.73% |
| 2016 | 68.4 Million SEK | 14.12% |
| 2015 | 59.94 Million SEK | 26.03% |
| 2014 | 47.56 Million SEK | 95.22% |
| 2013 | 24.36 Million SEK | 207.82% |
| 2012 | 7.91 Million SEK | 61.86% |
| 2011 | 4.89 Million SEK | 0.0% |
| 2009 | -20.16 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 27.8 Million SEK | 5.75% |
| 2024 Q2 | 17.28 Million SEK | -37.48% |
| 2023 Q3 | 17.03 Million SEK | 2.38% |
| 2023 Q4 | 26.28 Million SEK | 54.36% |
| 2023 FY | 83.09 Million SEK | -14.04% |
| 2023 Q1 | 22.31 Million SEK | -31.31% |
| 2023 Q2 | 16.63 Million SEK | -25.47% |
| 2022 Q3 | 22.9 Million SEK | 9.65% |
| 2022 Q4 | 32.49 Million SEK | 41.87% |
| 2022 FY | 96.67 Million SEK | 22.99% |
| 2022 Q1 | 20.38 Million SEK | -12.12% |
| 2022 Q2 | 20.88 Million SEK | 2.44% |
| 2021 Q2 | 21.79 Million SEK | 22.67% |
| 2021 Q4 | 23.2 Million SEK | 46.43% |
| 2021 FY | 78.59 Million SEK | -10.7% |
| 2021 Q1 | 17.76 Million SEK | -26.51% |
| 2021 Q3 | 15.84 Million SEK | -27.29% |
| 2020 Q1 | 20.73 Million SEK | -13.65% |
| 2020 Q4 | 24.16 Million SEK | 4.15% |
| 2020 Q3 | 23.2 Million SEK | 16.53% |
| 2020 Q2 | 19.91 Million SEK | -3.94% |
| 2020 FY | 88.02 Million SEK | 1.69% |
| 2019 FY | 86.55 Million SEK | 11.85% |
| 2019 Q4 | 24 Million SEK | 12.7% |
| 2019 Q2 | 19.57 Million SEK | -9.65% |
| 2019 Q1 | 21.66 Million SEK | 3.65% |
| 2019 Q3 | 21.3 Million SEK | 8.81% |
| 2018 Q4 | 20.9 Million SEK | 13.44% |
| 2018 FY | 77.38 Million SEK | 16.3% |
| 2018 Q3 | 18.42 Million SEK | 3.9% |
| 2018 Q2 | 17.73 Million SEK | -12.69% |
| 2018 Q1 | 20.31 Million SEK | 9.83% |
| 2017 FY | 66.53 Million SEK | -2.73% |
| 2017 Q4 | 18.49 Million SEK | 15.37% |
| 2017 Q1 | 17.46 Million SEK | -28.46% |
| 2017 Q2 | 14.54 Million SEK | -16.7% |
| 2017 Q3 | 16.03 Million SEK | 10.23% |
| 2016 Q2 | 15.37 Million SEK | 19.87% |
| 2016 Q3 | 15.79 Million SEK | 2.67% |
| 2016 Q4 | 24.4 Million SEK | 54.57% |
| 2016 Q1 | 12.83 Million SEK | -29.99% |
| 2016 FY | 68.4 Million SEK | 14.12% |
| 2015 Q3 | 14.44 Million SEK | 10.34% |
| 2015 FY | 59.94 Million SEK | 26.03% |
| 2015 Q4 | 18.32 Million SEK | 26.84% |
| 2015 Q1 | 14.07 Million SEK | -26.55% |
| 2015 Q2 | 13.09 Million SEK | -6.98% |
| 2014 Q4 | 19.16 Million SEK | 69.01% |
| 2014 Q1 | 8.42 Million SEK | -12.86% |
| 2014 Q3 | 11.33 Million SEK | 31.31% |
| 2014 Q2 | 8.63 Million SEK | 2.48% |
| 2014 FY | 47.56 Million SEK | 95.22% |
| 2013 Q2 | 3.87 Million SEK | 4.54% |
| 2013 Q4 | 9.66 Million SEK | 35.74% |
| 2013 FY | 24.36 Million SEK | 207.82% |
| 2013 Q3 | 7.12 Million SEK | 84.01% |
| 2013 Q1 | 3.7 Million SEK | 45.17% |
| 2012 FY | 7.91 Million SEK | 61.86% |
| 2012 Q3 | 2 Million SEK | -21.61% |
| 2012 Q2 | 2.55 Million SEK | 47.64% |
| 2012 Q1 | 1.73 Million SEK | 0.0% |
| 2012 Q4 | 2.55 Million SEK | 27.35% |
| 2011 Q2 | 1.32 Million SEK | 0.0% |
| 2011 FY | 4.89 Million SEK | 0.0% |
| 2011 Q3 | 1.68 Million SEK | 26.87% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q2 | 6121.00 SEK | 0.0% |
| 2010 Q3 | 161.08 Thousand SEK | 2531.61% |
| 2009 FY | -20.16 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -503.253% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | -108.889% |
| BioGaia AB (publ) | 507.08 Million SEK | 84.238% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | -109.085% |
| Gabather AB (publ) | 9.47 Million SEK | -743.625% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -436.986% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | -191.028% |
| Nanexa AB (publ) | 135.78 Million SEK | 41.137% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | -165.435% |
| ODI Pharma AB | -5.00 SEK | 1598500100.0% |
| Orexo AB (publ) | 659.4 Million SEK | 87.879% |
| Probi AB (publ) | 208.93 Million SEK | 61.746% |
| Swedencare AB (publ) | 1.12 Billion SEK | 92.913% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 99.149% |
| Toleranzia AB | 6.97 Million SEK | -1046.371% |
| Vivesto AB | 355.71 Million SEK | 77.531% |